News articles about Fresenius Medical Care AG & Co. (NYSE:FMS) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Fresenius Medical Care AG & Co. earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.2757507370102 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Fresenius Medical Care AG & Co. stock opened at $50.09 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $30.72 billion, a P/E ratio of 22.67, a P/E/G ratio of 2.96 and a beta of 0.79. Fresenius Medical Care AG & Co. has a one year low of $47.19 and a one year high of $57.94.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 31st. The company reported $0.54 EPS for the quarter, missing the Zacks’ consensus estimate of $0.60 by ($0.06). The company had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.28 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.78% and a net margin of 11.65%. Fresenius Medical Care AG & Co.’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 earnings per share. equities analysts predict that Fresenius Medical Care AG & Co. will post 2.39 earnings per share for the current fiscal year.

A number of equities analysts recently commented on FMS shares. DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, August 6th. Zacks Investment Research raised Fresenius Medical Care AG & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, May 29th. HSBC raised Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, Bank of America started coverage on Fresenius Medical Care AG & Co. in a research note on Monday, July 9th. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $54.67.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Featured Article: Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.